

Sanofi
Form 6-K
April 09, 2014

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April 2014

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐

No ☒

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: Sanofi - Form 6-K

In March and April 2014, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.4 which are incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated April 7, 2014: Genzyme to Resubmit Lemtrada Application for FDA Review
Exhibit 99.2	Press release dated March 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63rd Annual Scientific Session
Exhibit 99.3	Press release dated March 19, 2014: Sanofi Pasteur Allies with SK Chemical Co. of South Korea on Pneumococcal Conjugate Vaccine
Exhibit 99.4	Press release dated March 11, 2014: Sanofi and UCB Partner for Breakthrough Innovation in Immune-mediated Diseases

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 9, 2014

SANOFI

By /s/ John Felitti
Name:
Title:

John Felitti
Associate Vice President,
Corporate Law, Financial & Securities Law

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated April 7, 2014: Genzyme to Resubmit Lemtrada Application for FDA Review
Exhibit 99.2	Press release dated March 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63rd Annual Scientific Session
Exhibit 99.3	Press release dated March 19, 2014: Sanofi Pasteur Allies with SK Chemical Co. of South Korea on Pneumococcal Conjugate Vaccine
Exhibit 99.4	Press release dated March 11, 2014: Sanofi and UCB Partner for Breakthrough Innovation in Immune-mediated Diseases